Stockscreener 앱 받기
8.0788
1.60%
-0.1712
전일 마감가:
$8.25
열려 있는:
$8.19
하루 거래량:
164.78K
Relative Volume:
0.25
시가총액:
$5.51B
수익:
$8.62B
순이익/손실:
$573.80M
주가수익비율:
11.43
EPS:
0.707
순현금흐름:
$680.05M
1주 성능:
+2.37%
1개월 성능:
+6.68%
6개월 성능:
-13.64%
1년 성능:
-20.02%
1일 변동 폭
$8.06
$8.20
1주일 범위
$7.68
$8.38
52주 변동 폭
$6.96
$10.23
그리폴스 Stock (GRFS) Company Profile
Compare GRFS vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
8.09 | 5.61B | 8.62B | 573.80M | 680.05M | 0.707 |
LLY
Lilly Eli Co
|
1,264.56 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
270.54 | 658.89B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
264.87 | 470.00B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
151.20 | 375.50B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
157.38 | 304.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
그리폴스 Stock (GRFS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 재개 | Morgan Stanley | Overweight |
| 2024-03-12 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-04-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2023-01-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-04-08 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-10-19 | 다운그레이드 | Barclays | Overweight → Underweight |
| 2021-10-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-06-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2021-04-20 | 개시 | Deutsche Bank | Hold |
| 2021-03-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2020-10-01 | 업그레이드 | Citigroup | Sell → Neutral |
| 2020-06-09 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-06-09 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-03-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-06-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-02-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2018-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-06-01 | 개시 | Barclays | Overweight |
| 2017-10-31 | 개시 | Citigroup | Buy |
| 2017-06-30 | 다운그레이드 | Goldman | Buy → Neutral |
| 2017-04-06 | 개시 | BofA/Merrill | Buy |
| 2017-01-03 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-02-09 | 업그레이드 | Berenberg | Hold → Buy |
| 2016-01-04 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2015-11-20 | 다운그레이드 | Berenberg | Buy → Hold |
| 2015-04-28 | 다운그레이드 | Berenberg | Buy → Hold |
모두보기
그리폴스 주식(GRFS)의 최신 뉴스
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - tradingview.com
Grifols stock trades below $8 as investors weigh earnings outlook - Ad-hoc-news.de
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK
Grifols ADRs Drop 4% to $7.87 as GRFS Nears Key Support at $7.48Insider Buying Alerts - Vinanet
Grifols shares jump after Q2 results exceed expectations - Investing.com
Grifols, S.A. Sponsored ADR Class A Revenue Breakdown – MUN:G0F - TradingView
Grifols H1 2026 slides: cash flow surges as IG drives growth - Investing.com
Grifols SA (GRFS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Grifols, S.A. (GRFS) Stock Price, News, Quote & History - Yahoo! Finance Canada
[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Grifols doses first patients in two phase 3 immunoglobulin trials By Investing.com - Investing.com UK
G0FB Forecast — Price Target — Prediction for 2027 - TradingView
GRFSGrifols SA ADR Options - Finviz
G0F Forecast — Price Target — Prediction for 2027 - TradingView
Grifols operations profile, Sunday focus on plasma and strategy - ad-hoc-news.de
A1C3HH Forecast — Price Target — Prediction for 2027 - TradingView
Grifols, S.A. Class A Actuals & Estimates (BME:GRF) - TradingView
A1J1E2 Forecast — Price Target — Prediction for 2027 - TradingView
Grifols, S.A. Sponsored ADR Class B Actuals & Estimates (NASDAQ:GRFS) - TradingView
Grifols holds technical support, shares trade in a tight Nasdaq range - AD HOC NEWS
Grifols S.A. Stock (ES0171996087): IBEX 35 plasma specialist in focus after modest gain - Ad-hoc-news.de
GRIFOLS SA-ADR (GRFS) Stock Chart - ChartMill
Grifols Shares Edge Lower as Stock Tests Key Support ZoneVolatility Smirk - newsline.com
Grifols ADR (GRFS) Gains 1.47% as Shares Hold Above Key Support LevelSector Leader Stocks - newsline.com
Grifols S.A. stock (ES0171996087): Q1 2026 figures and rising short interest keep focus on Spanish p - AD HOC NEWS
Grifols S.A. stock (ES0171996087): Spain plasma specialist in focus after volatile trading week - AD HOC NEWS
GRFS Stock Price, Quote & Chart | GRIFOLS SA-ADR (NASDAQ:GRFS) - ChartMill
Grifols S.A. stock (ES0171996087): Debt reduction deal, Q1 update and what matters for US investors - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist regains momentum after earnings update - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist back in focus after debt and governance reset - AD HOC NEWS
Grifols SA stock (ES0171996087): AGM plans and Moody’s outlook shift put debt and governance back - AD HOC NEWS
Grifols SA stock (ES0171996087): shareholders eye 2026 AGM after Moody’s outlook boost - AD HOC NEWS
Brandes reports 24.31% stake in Grifols (NASDAQ: GRFS) in Schedule 13G/A - Stock Titan
Earnings call transcript: Grifols Q1 2026 sees mixed results with EPS beat - Investing.com
Grifols S.A. stock (ES0171996087): Leading player in plasma-derived medicines - AD HOC NEWS
Grifols S.A. stock (ES0171996087): Plasma therapy specialist faces pricing and regulatory headwinds - AD HOC NEWS
Earnings call transcript: Grifols Q1 2026 results show mixed signals, revenue miss - Investing.com
Grifols Q1 Earnings Call Highlights - Barchart
Mittleman Value Partners 2025 Year-End & Q1 2026 Investment Review - Seeking Alpha
Grifols (NASDAQ: GRFS) 2025 revenue rises as leverage and risk factors stay elevated - Stock Titan
CapEx per share of Grifols, S.A. Sponsored ADR Class B – LSX:A1J1E2 - TradingView
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
그리폴스 (GRFS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
0.13%
자본화:
|
볼륨(24시간):